Our patient tumor sequencing data shows the overexpression of AURKA and AURKB (average Z-score = 2.33 and 2.18, respectively); the result that Panobinostat decreases AURKB shows again that it is targeting another pathway which may be playing an important role in tumor progression. This evidence concerns the gene AURKA and neoplasm.